Harvard Bioscience, Inc.
General ticker "HBIO" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $24.3M (TTM average)
Harvard Bioscience, Inc. follows the US Stock Market performance with the rate: 34.1%.
Estimated limits based on current volatility of 2.8%: low 5.89$, high 6.22$
Factors to consider:
- Total employees count: 339 (-4.5%) as of 2025
- China accounted for 14.1% of revenue in the fiscal year ended 2024-12-31
- US accounted for 44.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Product development failure, Customer industry downturns, Geopolitical risks, Regulatory and compliance
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.28$, 13.47$]
- 2026-12-31 to 2027-12-31 estimated range: [5.92$, 14.26$]
Financial Metrics affecting the HBIO estimates:
- Positive: with PPE of -180.0 at the end of fiscal year the price was neutral
- Positive: Operating cash flow per share per price, % of 21.06 > 12.93
- Positive: -5.34 < Operating profit margin, % of -0.72
- Positive: -0.03 < Industry operating cash flow per share per price (median), % of 1.67
- Positive: Inventory ratio change, % of -0.41 <= 0
- Positive: -9.70 < Industry operating profit margin (median), % of -3.62
- Negative: negative Net income
Short-term HBIO quotes
Long-term HBIO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $112.25MM | $94.14MM | $86.55MM |
| Operating Expenses | $110.36MM | $100.35MM | $134.60MM |
| Operating Income | $1.89MM | $-6.21MM | $-48.05MM |
| Non-Operating Income | $-4.45MM | $-5.45MM | $-9.34MM |
| Interest Expense | $3.59MM | $3.54MM | $4.92MM |
| R&D Expense | $11.76MM | $10.41MM | $8.82MM |
| Income(Loss) | $-2.56MM | $-11.66MM | $-57.39MM |
| Taxes | $0.86MM | $0.74MM | $-0.69MM |
| Net Income(Loss)* | $-3.42MM | $-12.40MM | $-56.70MM |
| Stockholders Equity | $73.07MM | $63.34MM | $13.73MM |
| Inventory | $24.72MM | $23.25MM | $20.80MM |
| Assets | $137.37MM | $126.64MM | $80.07MM |
| Operating Cash Flow | $14.03MM | $1.44MM | $6.73MM |
| Capital expenditure | $2.31MM | $3.26MM | $1.11MM |
| Investing Cash Flow | $-1.80MM | $-1.34MM | $-1.86MM |
| Financing Cash Flow | $-12.13MM | $-0.13MM | $-1.29MM |
| Earnings Per Share** | $-0.81 | $-2.85 | $-12.77 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.